Helus Pharma is led by Chief Executive Officer Michael Halstead, an experienced biopharmaceutical executive who took the helm to guide the company through its late-stage clinical development and commercialization phases. Prior to his appointment, he served in prominent leadership roles at other prominent life sciences enterprises, helping shepherd organizations from early-stage clinical work into fully integrated commercial biopharmaceutical entities. His executive mandate focuses on steering the company's core psychedelic and novel serotonergic agonist pipeline candidates—such as HLP003 and HLP004—through ongoing pivotal clinical trials and regulatory review processes.